ARGNF News and Press, Argen X NV From 07/19/23

2023-07-19 17:50:15 ET Summary Immunovant, Inc. received additional validation with anti-FcRn achieved as competitor argenx achieves primary endpoint in phase 2 study using VYVGART for the treatment of patients with CIDP. Immunovant expects to release results from its phase 2b stu...

Regulated information — Inside information July 18, 2023, 9:20 PM ET July 19, 2023, 3:20 AM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people su...

Regulated information — Inside information argenx announces launch of proposed global offering July 17 , 2023 Amsterdam , the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the live...

Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG autoantibodies shown to play significant role in underlying CIDP disease biology Favorable safety and tolerability profile ...

2023-07-16 07:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Mid cap stocks generat...

First - and - only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with...

2023-06-29 21:55:49 ET Summary argenx has received approval for the subcutaneous version of efgartigimod, a drug for treating myasthenia gravis, but the market did not respond positively to the news, and the company's share price remained relatively stable. The drug's label did no...

VYVGART ® Hytrulo is first FDA - approved subcutaneous (SC) inject able for generalized myasthenia gravis ( gMG ) With this approval, argenx broadens innovative gMG product offering and demonstrates continued...

Independent Data Monitoring Committee recommend ed study continuation based on the favorable safety profile observed in the first dose cohort Early efficacy signals support proof-of-concept of empasiprubart in multifo...

2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...